Randomized, placebo-controlled, phase III trial of yeast- derIVed granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: A trial of the eastern cooperatIVe oncology groupâ€"American college of radiology imaging network cancer research group (E4697)

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 4066-4076

  Lawson, David H ^a   Lee, Sandra ^b   Zhao, Fengmin ^b   Tarhini, Ahmad A ^d   Margolin, Kim A ^e   Ernstoff, Marc S ^f   Atkins, Michael B ^c   Cohen, Gary I ^g   Whiteside, Theresa L ^d   Butterfield, Lisa H ^d   Kirkwood, John M ^d  

^a EMORY UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; GP 100 209 217(210M); HLA A2 ANTIGEN; MART 1 (27-35); MONTANIDE ISA 51; PEPTIDE VACCINE; PLACEBO; SARGRAMOSTIM; TYROSINASE 368 376(370D); UNCLASSIFIED DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE FRAGMENT; SUBUNIT VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; FEMALE; HUMAN; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUCOSAL MELANOMA; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF RADIOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SECOND CANCER; UVEA MELANOMA; VACCINATION; VERY ELDERLY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; IMMUNOLOGY; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE; VACCINATION; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 84951828193     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.0500     Document Type: Article

References (18)

1. Lawson D, Kirkwood JM: Granulocytemacrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol 18:1603-1605, 2000
2. Wing EJ, Magee DM, Whiteside TL, et al: Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 73:643-646, 1989
3. Grabstein KH, Urdal DL, Tushinski RJ, et al: Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232:506-508, 1986
4. Bell D, Young JW, Banchereau J: Advances in immunology. Adv Immunology 72:255-324, 1999
5. Dong Z, Kumar R, Yang X, et al: Macrophagederived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801-810, 1997
6. Spitler LE, Grossbard ML, Ernstoff MS, et al: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor. J Clin Oncol 18:1614-1621, 2000
7. Spitler LE, Weber RW, Allen RE, et al: Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother 32:632-637, 2009
8. Grotz TE, Kottschade L, Pavey ES, et al: Adjuvant GM-CSF improves survival in high-risk stage IIIC melanoma: A single-center study. Am J Clin Oncol, 37:467-472, 2014
9. Daud AI, Mirza N, Lenox B, et al: Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocytemacrophage colony-stimulating factor. J Clin Oncol 26:3235-3241, 2008
10. Astsaturov I, Petrella T, Bagriacik EU, et al: Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-Alpha2b: Implications for cancer vaccines. Clin Cancer Res 9:4347-4355, 2003
11. Chianese-Bullock KA, Pressley J, Garbee C, et al: MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 174:3080-3086, 2005
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
13. Kirkwood JM, Lee S, Moschos SJ, et al: Immunogenicity and antitumor effects of vaccination with peptide vaccine/-granulocyte-monocyte colony-stimulating factor and/or IFN-Alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group phase II trial E1696. Clin Cancer Res 15:1443-1451, 2009
14. Flaherty LE, Othus M, Atkins MB, et al: Southwest Oncology Group S0008: A phase III trial of high-dose interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma-An intergroup study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol 32:3771-3778, 2014
15. Lawson DH, Lee SJ, Tarhini AA, et al: E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 28:612s, 2010 (abstr 8504)
16. Gogas H, Kirkwood JM, Falk CS, et al: Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 116:4326-4333, 2010
17. Kirkwood JM, Richards T, Zarour HM, et al: Immunomodulatory effects of high-dose and low-dose interferon alpha-2b in patients with highrisk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101-1112, 2002
18. Hodi FS, Lee S, McDermott DF, et al: Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA 312:1744-1753, 2014